STAT+: Merck reaches deal with Austrian antitrust regulators over ‘predatory’ pricing for a cancer drug

Following a three-year probe, Merck (MRK) reached a deal with Austrian regulators to end a “predatory” pricing strategy for a brain cancer treatment, the latest instance in which European authorities have scrutinized the pharmaceutical industry over anticompetitive practices.

The focus of the investigation was Temodal, which is used to treat such brain tumors as glioblastoma, the most frequent type of brain tumor in adults. Approximately 350 people develop this malady in Austria each year, but the Federal Competition Authority determined the company was making it difficult for lower-cost generic versions to reach the market.

Continue to STAT+ to read the full story…

STAT+: Merck reaches deal with Austrian antitrust regulators over ‘predatory’ pricing for a cancer drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top